Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $13.21
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 29, 26 | Citigroup | upgrade | Sell | Buy |
| Jun 5, 25 | HSBC | upgrade | Hold | Buy |
| Nov 6, 24 | Barclays | maintain | Overweight | Overweight |
| Jul 30, 24 | Barclays | maintain | Overweight | Overweight |
| May 8, 24 | Barclays | maintain | Overweight | Overweight |
| Jan 29, 24 | Barclays | maintain | Overweight | Overweight |
| Jun 1, 23 | Barclays | maintain | Overweight | Overweight |
| Oct 31, 22 | Barclays | maintain | Overweight | Overweight |
| Oct 25, 22 | Barclays | maintain | Overweight | Overweight |
FY2026 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | RDY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 31.0x | 21.2x · sector 20.7x | Elevated |
| Forward P/E (FY27E) | 0.3x | EPS est. 42.45 | Discount |
| Price / Book | 2.7x | 3.3x | Discount |
| Price / Sales | 3.1x | 3.2x | In line |
| EV / EBITDA | 16.3x | 12.4x | Elevated |
| Return on equity | 8.9% | — | Weak |
| Gross margin | 50.2% | 55.9% | In line |
| Debt / Equity | 0.19 | 0.13 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 5.30 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Apr 1, 26 | Munnirpallam Madhu Sundar Subramanian | officer: Global Head of Quality and PV | 0 | — | |
| 6-K | Oct 21, 2026 | 2026-10-21 06:21:02 | View |
| 6-K | Oct 14, 2026 | 2026-10-14 12:43:28 | View |
| 6-K | Oct 8, 2026 | 2026-10-08 09:30:28 | View |
| 6-K | Oct 7, 2026 | 2026-10-07 06:55:57 | View |
| 6-K | Oct 5, 2026 | 2026-10-05 06:09:50 | View |
| 6-K | Sep 22, 2026 | 2026-09-22 14:19:17 | View |
Proxy statement (DEF 14A) disclosures
| Dec 18, 25 |
| Aghanian Patrick Rudolf |
| officer: Head - Europe Generics |
| 0 |
| — |
| Dec 18, 25 | Kalawadia Milan Kantilal | officer: CEO - North America | 0 | — |
| Dec 18, 25 | Motupalli Venkata Ramana | officer: CEO - Global Generics | 0 | — |
| Dec 18, 25 | Israeli Erez | officer | 0 | — |
| Dec 18, 25 | Venkatesh Krishna | officer | 0 | — |
| Dec 18, 25 | Kulkarni Sushrut | officer: GLOBAL HEAD - IPDO | 0 | — |
| Dec 18, 25 | Bhethanabottla Srinivasa Phanimitra | officer: Chief Information Officer | 0 | — |
Stock news · updated daily
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
Dr. Reddy's Laboratories Ltd (NYSE: RDY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.92 and traded as high as $12.94. Dr. Reddy's Laboratories shares last traded at $12.7650, with a volume of 3,738,869 shares traded. Wall Street Analyst Weigh
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 23, 2026 | 0.09 | 0.12 | Beat 26.9% | — |
| Jul 21, 2026 | 0.09 | 0.06 | Miss -34.7% | $835.7M |
| May 11, 2026 | 0.09 | 0.06 | Miss -33.3% | $785.9M |
| Jan 20, 2026 | 0.16 | 0.16 | Beat 0.0% | $951.6M |
| Oct 24, 2025 | 0.18 | 0.19 | Beat 5.6% | $1.00B |
| Jul 23, 2025 | 0.18 | 0.20 | Beat 11.1% | $988.9M |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 68.09 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 89.11 | Oscillator | Sell |
| Williams %R (14) | -12.09 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.27 (Hist 0.07) | Oscillator | Strong Buy |
| Average Directional Index (14) | 19.89 (+DI 38.1 / -DI 20.0) | Trend | Neutral |
| EMA 20 | 12.81 | MA | Strong Buy |
| SMA 20 | 12.73 | MA | Strong Buy |
| EMA 50 | 12.59 | MA | Strong Buy |
| SMA 50 | 12.36 | MA | Strong Buy |
| SMA 200 | 13.20 | MA | Buy |